Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of nivolumab + ipilimumab or nivolumab + platinum-doublet chemotherapy versus platinum-doublet chemotherapy in resectable early non-small cell lung cancer
CTR20180929Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20180929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180929.